Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
Kadoglou
Nikolaos P E
NP
1st Propedeutic Department Internal Medicine, AHEPA University Hospital, Thessaloniki, Greece. nikoskad@yahoo.com
Iliadis
Fotios
F
Liapis
Christos D
CD
Perrea
Despina
D
Angelopoulou
Nikoleta
N
Alevizos
Miltiadis
M
D000368:Aged; D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy*; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000628:therapy*; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone